Pindolol (pindolol)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Pindolol is a nonselective beta-adrenergic blocking agent (beta-blocker) possessing intrinsic sympathomimetic activity.
Pindolol is used in the management of hypertension. The drug also has been used in the management of angina+.
Generic name: pindolol
Pronunciation: (PIN-doe-lol)
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Pindolol
Indications
The following indications are listed for Pindolol:
- Hypertension
Also known as: Elevated Blood Pressure, Essential Hypertension, Hyperpiesia, Hyperpiesis, Hypertensive Disorder, Systemic Arterial Hypertension.
Dosing
Dosage of pindolol must be individualized and adjusted according to the patient's response and tolerance. If long-term pindolol therapy is to be discontinued, dosage of the drug should be gradually reduced over a period of 1-2 weeks. (See Cautions: Precautions and Contraindications.)
In patients with hepatic impairment, doses and/or frequency of administration of pindolol must be modified in response to the degree of hepatic impairment.
Pindolol is administered orally.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
There is no enhanced messaging for this drug.
There are no contraindication contraindications for this drug.
There are no severe contraindications for this drug.
There are no moderate contraindications for this drug.
Adverse reactions
There is no enhanced messaging for this drug.
There are no severe adverse reactions for this drug.
There are no less severe adverse reactions for this drug.
Precautions
No enhanced messaging available.
No enhanced messaging available.
Reproduction studies in rats and rabbits using doses exceeding 100 times the recommended maximum human doses have not revealed any evidence of embryotoxicity or teratogenicity. There are no adequate and controlled studies to date using pindolol in pregnant women, and the drug should be used during pregnancy only when the potential benefits justify the possible risks to the fetus.
Nursing should not be undertaken in women receiving pindolol, since the drug is distributed into milk.
No enhanced messaging available.
ICD codes
No ICD codes are available for this drug.
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.